Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
NEW YORK, Aug. 26, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) securities February 25, 2016 and August 1, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/keryx-biopharmaceuticals. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company was experiencing production-related difficulties in converting API to finished drug product; (2) that the issue was resulting in decreased production yields of finished drug product; (3) that, as a result, the Company would, and did exhaust its reserve of finished drug product; and (4) that, as a result of the foregoing, Defendants’ statements about Keryx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Keryx Biopharmaceuticals you have until October 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/keryx-biopharmaceuticals.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
